

Patent Selections:

The patents annotated in this section have been selected from various patent collections. They are recent patents categorized by therapeutic area/agent/target and therapeutic agents related to anti-infective drug discovery and are relevant to the articles published in this journal issue.

HIV-1 INHIBITORS

1. Wang, L.-X., Ni, J., Li, H., Singh, S. Scaffolded maleimide clusters for multivalent peptide assembly *US20050159341A1* (2005).
2. Wu, W., Liao, H., Tsai, D.J.S., Andrews, D.R., Gala, D., Lee, G.M., Schwartz, M.L., McAllister, T.L., Fu, X., Maloney, D. Thiruvengadam, T.K., Tann, C.-H. Stereoselective alkylation of chiral 2-methyl-4-protected piperazines *US6872826* (2005).
3. Kappes, J., Wu, X. Cell-based method and assay for measuring the infectivity and drug sensitivity of immunodeficiency virus *US20050032046A1* (2005).
4. Wallner, B.P., Miller, G. Anti-tumor agents *US6949514* (2005) and *US6890904* (2005).
5. Anthony, N.J., Xu, W., Lepore, J.V., Mahajan, A.J. Sodium salt of an HIV integrase inhibitor *US6924282* (2005).
6. Dong, J.-Y. Methods of monitoring HIV drug resistance *US6884576* (2005).
7. Bachovchin, W.W. Multivalent compounds for crosslinking receptors and uses thereof *US6875737* (2005).

C5A

1. Cleary, P.P., Stafslie, D.K. Streptococcal C5a peptidase vaccine *US6951653* (2005).
2. Taylor, F.B. Jr., Bajzar, L. Treatment of sepsis with TAFI *US6838432* (2005).
3. Ishibuchi, S., Sumichika, H., Itoh, K., Naka, Y. 3-Substituted urea derivatives and medicinal use thereof *EPI308438A4* (2005).
4. Nakamura, M., Kamahori, T., Ishibuchi, S., Naka, Y., Sumichika H., Itoh K. Novel amide derivatives and medicinal use thereof *EPI318140A4* (2005).

INNATE IMMUNITY AND INFECTION

1. Bauer, S., Lipford, G., Wagner, H., Nucleic acids for high throughput screening of CpG-based immunagonist/antagonist *US6943240* (2005).
2. Lamberty, M., Bulet, P., Brookhart, G., Hoffman, J., Gene coding for heliomicine and use thereof *US6916782* (2005).
3. Serhan, C.N. Lipoxin compounds and their use in treating cell proliferative disorders *US6887901* (2005).
4. Egorov, A., Muster, T., Garcia-Sastre, A., Palese, P., Brandt, S. Interferon inducing genetically engineered attenuated viruses *US6866853* (2005).

5. Palese, P., Garcia-Sastre, A., O'Neil, R., Methods and interferon deficient substrates for the propagation of viruses *US6852522* (2005).
6. Tuggle, C.K., Marklund, L., Stabel, T.J., Mellencamp M.A., Stumbaugh, A. Genetic markers for screening animals for improved disease resistance (NRAMP). *US6844159* (2005).
7. Whitsett, J.A. Surfactant protein D for the prevention and diagnosis of pulmonary emphysema *US6838428* (2005).

SEPSIS AND INFECTION

1. Porro, M. Vaccine for prevention of gram-negative bacterial infections and endotoxin related diseases *US6951652* (2005).
2. Davis, K.A. Methods and reagents for quantitation of cell-surface molecule expression on peripheral blood cells *US6951727* (2005).
3. Hansen, P., Pettersson, L. Compounds *US6951874* (2005).
4. Pettersson, L., Hansen, P. Compounds *US6927222* (2005).
5. Riggs, R.S., Moore, G. Treatment of sepsis *US20050197321A1* (2005).
6. Reed, J.C., Godzik, A., Pawlowski, K., Fiorentino, L., Lee, S.H., Roth, W., Stenner-Liewen, F. Novel death domain proteins *US20050192427A1* (2005).
7. Frohn, M.J., Hong, F.-T., Liu, L., Lopez, P., Siegmund, A., Tadesse, S., Tamayo, N. Substituted heterocyclic compounds and methods of use *US20050187223A1* (2005).
8. Wang, P. Treatment of shock using adrenomedullin binding protein-1 *US20050181983A1* (2005).
9. Hartmann, G., Bratzler, R.L., Krieg, A.M. Methods related to immunostimulatory nucleic acid-induced interferon *US6949520* (2005).
10. Schumann, R.R., Lamping, N. Therapeutic agent for the treatment of septicemia its preparation and use *US6949512* (2005).
11. Eriksson, T., Hansen, P., Hemmerling, M., Henriksson, K., Klingstedt, T., Pettersson, L., Bodkin, M. Hydroxy-alkyl compounds *US6943188* (2005).
12. Bermudes, D., Low, K.B. Methods for use of genetically modified tumor-targeted bacteria with reduced virulence *US6923972* (2005).

13. Zlotnick, G.W. Preparation and uses of los-depleted outer membrane proteins of gram-negative cocci *US6921537 (2005)*.
 14. Eriksson, T., Klingstedt, T., Mussie, T. Compounds *US6911458 (2005)*.
 15. Ni, J., Li, H., Su, J. Chemokine alpha 3 *US6908986 (2005)*.
 16. Bermudes, D., Low, K.B. Genetically modified tumor-targeted bacteria with reduced virulence *US6863894 (2005)*.
 17. Kimura, H., Sato, Y., Takizawa, M., Horiguchi, T., Notoya, K. Cell death inhibitor *EPI500402A1 (2005)*.
 18. Beyaert, R., Janssens, S. Novel splice variant of MyD88 and uses thereof *US20050181476A1 (2005)*.
 19. Shaunak, S., Gianasi, E., Duncan, R. Glycodendrimers having biological activity *US20050214247A1 (2005)*.
 20. Granger, G.A., Gatanaga, T. Treating arthritis with TNF receptor releasing enzyme *US6930084 (2005)*.
 21. Larsen, C.G., Gesser, B. Synthetic IL-10 analogues *US6936586 (2005)*.
 22. Reineke, T. M. Polyamides for nucleic acid delivery *WO05062854A2 (2005)*.
 23. Patti, J., Vernachio J., Liu Y., Hook M., Bowden M., Singvall J.K. Method of inhibiting Candida-related infections using donor selected or donor stimulated immunoglobulin compositions *WO05060713A2 (2005)*.
 24. Bakhutashvili, V., Haller, J. D., Bakhutashvili, I., Bakhutashvili, A., Nicoletti, F., Hirya, M., Poncin, A. Amniotic-derived peptide and uses thereof *WO05049638A2 (2005)*.
 25. Brines, M., Cerami, A., Yilmaz, O., Coleman, T. Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions *WO05032467A2* and *WO05032467A3 (2005)*.
 26. Kirschning, C.J., Meng, G., Wagner, H. TLR2 antagonistic antibody and use thereof *WO05028509A1 (2005)*.
 27. Dominquez, C., Harvey, T. S., Liu, L., Siegmund, A. Substituted pyridones and pyrimidinones with antiinflammatory properties *WO05012286A1 (2005)*.
 28. Burnie, J., Matthews, R.C., Treatment of *E. faecium* infection *US6881410 (2005)*.
 29. Bock, S.C., Picard, V., Zendeherouh, P. Human antithrombin IIIs and methods related thereto *US6878813 (2005)*.
 30. Gatanaga, T., Granger, G.A. System for discovering and producing polypeptides that cause TNF receptor shedding *US6858402 (2005)*.
 31. Bergmann, A., Struck, J., Uhlein, M. Uses of aldose-1-epimerase (mutarotase) for diagnosis and therapy of inflammatory diseases and sepsis *US20050130242A1 (2005)*.
 32. Lipford, G.B. Forsbach, A., Zepp, C. Small molecule toll-like receptor (TLR) antagonists *US20050119273A1 (2005)*.
 33. Dixit, V.M., He, W.-W., Kikly, K. K., Ruben, S. M. Interleukin-1 beta converting enzyme like apoptotic protease 6 *US20050089984A1 (2005)*.
 34. Heinecke, J. W. Method for detecting conditions indicative of sepsis *US6939716 (2005)*.
 35. Jones, K.W. Oligonucleotide decoys and methods of use *WO05079217A2 (2005)*.
 36. Frohn, M. J., Hong, F.T., Liu, L., Lopez, P., Siegmund, A.C., Tadesse, S., Tamayo, N. Substituted heterocyclic compounds and methods of use *WO05070932A2 (2005)*.
 37. Djurup, R., Flodgaard, H.J., Norris, K. Pro-inflammatory and anti-inflammatory antibodies against the heparin-binding protein (HBP) *WO05028512A1 (2005)*.
 38. Liu, L., Lopez, P., Bajpai, M., Siegmund, A.C. Substituted pyrimidinone derivatives and methods of use *WO05019202A1 (2005)*.
 39. Lipford, G.B., Forsbach, A., Zepp, C.M. Small molecule toll-like receptor (TLR) antagonists *WO05007672A3* and *WO05007672A2 (2005)*.
- #### SCAVENGER RECEPTOR
1. Fischer, G. W., Schuman, R.F., Wong, H., Stinson, J.R. Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria *US6939543 (2005)*.
 1. Bocharov, A. V., Baranova, I.N., Csako, G., Eggerton, T. L., Patterson, A. L., Remaley, A.T., Vishnyakova, T. V. Scavenger receptor 1 (CLA-1) targeting for the treatment of infection, sepsis and inflammation *EPI558275A2 (2005)*.
 3. Brodde, M., Kehrel, B. Medicament containing activated and cleaved antithrombin III *NZ0525292A (2005)*.
 4. Salfeld, J.G., Allen, D.J., Kaymakcalan, Z. Medical treatment with human TNF-alpha antibodies *NZ0512006A (2005)*.
 5. Dixit, V. M., He, W.-W., Kikly, K.K., Zuben, S.M. Interleukin-1 converting enzyme like apoptotic protease-6 *US6890721 (2005)*.
 6. Ramachandran, J., Padmanabhan, S., Sriram, B. Lysin-deficient bacteriophages having reduced immunogenicity *US6896882 (2005)*.
 7. Warne, N.W., Bedrosian, C.L., Keith, J.C. Jr., Schwertschlag, U.S., Schendel, P.F. Method of using IL-11 for treating mucositis *US6887461 (2005)*.
 8. Ramachandran, J., Padmanabhan, S., Sriram, B. Lysin-deficient bacteriophages having reduced immunogenicity *US6896882 (2005)*.
 9. Teti, G., Polonelli, L. Vaccine formulations comprising antiidiotypic antibodies which immunologically mimic

- group B streptococcal carbohydrates *US6900302 (2005)*.
- Althaus, H., Hauser, H.-P. Human Procalcitonin and the preparation and use thereof *US6905687 (2005)*.
 - Dominguez, C., Zhang, D., Sham, K., Elvin, K.C., Cao, G.Q. 1, 4, 5-Substituted 1, 2-dihydro-pyrazol-3-one and 3-alkoxy-1H-pyrazole derivatives TNF-alpha and interleukin lowering agents for the treatment of inflammations *WO04022055B1 (2005)*.

ANTIFUNGAL COMBINATION THERAPY

- Plourde, P., Rogers, A., Vose, B., Dukes, M. Use of anastrozole for the treatment of post-menopausal women having early breast cancer *US20050165081A1 (2005)*.
- Bartizal, K.F., Abruzzo, G.K. Flattery A. M. Antifungal combination therapy *CY0002481A (2005)*.

PEGYLATED INTERFERONS AND INFECTION

- Hudyma, T.W., Zheng, X., Romine, J. L. Inhibitors of HCV replication *US20050119318A1 (2005)*.

CHRONIC HEPATITIS B TREATMENT

- Erion, M.D., Reddy, K.R., Robinson, E.D., Ugarkar, B.G. Prodrugs for phosphorus-containing compounds *US6946115 (2005)*.
- Gold, D. P., Shopes, R. J. Method and composition for altering a B cell mediated pathology *US6911204 (2005)*.
- George, R., Tyrrell, L., Noujaim, A., Wang, D. Chimeric antigens comprising an FC-fragment for eliciting an immune response *WO05087813A1 (2005)*.
- Friedman, S., Albanis, E. Treatment of hepatic fibrosis with imatinib mesylate *US20050143389A1 (2005)*.
- Friedman, S., Albanis, E. Treatment of hepatic fibrosis with imatinib mesylate *WO05065690A1 (2005)*.
- Chu, C.K., Kotra, L.P., Manouilov, K., Du, J., Schinazi, R. Therapeutic azide compounds *US69495219 (2005)*.
- Korba, B.E., Ciancio, A., Gerin, J.L. Diagnostic for long term response of HBV carrier to 3TC therapy *US20050053916A1 (2005)*.
- Sallberg, M., Flock, J.-I. Specificity exchangers that redirect antibodies to bacterial adhesion receptors *US6933366 (2005)*.
- Rosen, C.A., Haseltine, W. A. Albumin fusion proteins *US6905688 (2005)*.
- Rosen, C.A., Haseltine, W. A. Albumin fusion proteins *US6926898 (2005)*.
- Skurkovich, B., Skurkovich, S.V. Treatment of AIDS with antibodies to gamma interferon, alpha interferon and TNF-alpha *US6863890 (2005)*.
- Houghton, M., Choo, Q.-L., Kuo, G. NANBV diagnostics and vaccines *US6861212 (2005)*.
- Rosen, H.R. Methods for identifying a preferred liver transplant donor *US6844156 (2005)*.

- Diamond, D.J. Immuno-reactive peptide CTL epitopes of human cytomegalovirus *US6843992 (2005)*.
- Smith, K.A. Low dose IL-2 for potentiation of immunity *US6921530 (2005)*.
- Chisari, F.V. Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus *US6919203 (2005)*.
- Sällberg, M., Hultgren, C. Vaccines containing ribavirin and methods of use thereof *US6858590 (2005)*.
- Wu, T.-S. Pharmaceutical composition having prophylactic effects on lamivudine-related disease relapse and drug resistance and methods of using the same *US6855346 (2005)*.

LAMIVUDINE

- Prasad, V.R., Joshi, P. Aptamer constructs *US20050222400A1 (2005)*.
- Chu, C. K., Schinazi, R.F. Dioxolane thymine and combinations for use against 3tc/azt resistant strains of HIV *US20050209196A1 (2005)*.
- Currie, R., Goodson, G. W. Pharmaceutical compositions comprising abacavir and lamivudine *US20050171127A1 (2005)*.
- Belleau, P., Dixit, D. M., Nguyen-Ba, N., Belleau, B. Substituted 1, 3-oxathiolanes *US6903224 (2005)*.
- De Corte, B., De Jonge, M.R., Heeres, J., Ho, C.Y., Janssen, P.A.J., Kavash, R.W., Koymans, L.M. H., Kukla, M.J. HIV replication inhibiting pyrimidines. *US6878717 (2005)*.
- Dunn, B.M., Yamamoto J.K. Combination therapy for treatment of FIV infection *US6875773 (2005)*.
- Parkin, N.T., Ziermann, R.A. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS *US6869759 (2005)*.
- Goodson, G. W., Wood A., Ford K.J. Pharmaceutical compositions containing lamivudine and zidovudine *SK0284286B6 (2005)*.
- Ichida, T., Kawashima Y. Hepatitis B virus proliferation inhibitor *EP1421949A4 (2005)*.
- Wu, T.-S. Pharmaceutical composition having prophylactic effects on lamivudine-related disease relapse and drug resistance and methods of using the same *EP1476174A4 (2005)*.
- Sen, H., Jayanthi, S.K. Long acting compositions comprising zidovudine and lamivudine *US20050175694A1 (2005)*.
- Ying-Kit, L. Use of thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir in manufacturing pharmaceutical combination preparations for treating hepatitis B infection *HK1041215A1 (2005)*.

13. Lee L.-T., Chang, S.-F., Lee, C.-Yu., Chiou, S.-J., Tong, T.-S. Extract from the roots or stems of Urticaceae for hepatitis B therapy *US20050136142A1 (2005)*.
14. Suzuki, Y., Kumada, H. Method for predicting the severity of viral hepatitis type B in patients treated with an anti-viral agent, and a kit for diagnosing viral hepatitis type B *US20050106561A1 (2005)*.
15. Goodson, G., Wood, A., Ford, K. Pharmaceutical compositions containing lamivudine and zidovudine and the use thereof *BG0064541B1 (2005)*.
16. Nguyen, N.A.T., Casey, W.M. Pharmaceutical compositions *EP0969815B1 (2005)*.
17. Standring, D., Sommadossi, J.-P., Patty, A.L., Seifer, M. Beta-L-2'-deoxynucleosides for the treatment of resistant HBV strains and combination therapies *US20050080034A1 (2005)*.
18. Sen, H., Jayanthi, S., Raghavan, V., Arra, G.S. A Controlled release pharmaceutical composition and a process for preparing the same *WO05048978A2 (2005)*.
19. Stoffels P. Combinations of a pyrimidine containing nrtti with RT inhibitors *WO05021001A1 (2005)*.

DEFOVIR

1. Cihlar, T., Douglas, J.L., Gibbs, C.S. Use of adefovir or tenofovir for inhibiting MMTV-like viruses involved in breast cancer and primary biliary cirrhosis *WO05072748A1 (2005)*.
2. Delaney, W.E., Xiong, X. HBV mutations associated with reduced susceptibility to adefovir *EP1546190A2 (2005)*.
3. Tianjin, K. Pharmaceutical Co., LTD. A new crystal form of adefovir dipivoxil and its composition *GB0511839A0 (2005)*.

ENTECAVIR

1. Colonna, R.J., Sprockel, O.L., Harianawala, A., Desai, D., Fakes, M.G. Low dose entecavir formulation and use in treating hepatitis b virus infection *NZ0520024A (2005)*.
2. Desai, D., Li, D. Low dose liquid entecavir formulations and use *EPI492510A1 (2005)*.

BENZOQUINONE AND INFECTION

1. Rosen, N., Srethapakdi, M. Methods for treating cell proliferative disorders and viral infections *US6946456 (2005)*.
2. Hofmann, R.F. Targeted oxidative therapeutic formulation. *US20050148569A1 (2005)*.

NAPHTHOQUINONE AND INFECTION

1. Hurston, D.E., Howard, P.W. Cyclopropylindole derivatives *US6909006 (2005)*.

ANTHRAQUINONE AND INFECTION

1. Manoharan, M., Cook, P.D., Bennett, C.F. Derivatized oligonucleotides having improved uptake and other properties *US6919439 (2005)*.

2. Cichewicz, R.H., Nair, M.G., McKerrow, J.H. Antihelminthic anthraquinones and method of use thereof *US6903076 (2005)*.
3. Cichewicz, R.H., Nair, M.G., McKerrow, J.H. Antihelminthic anthraquinones and method of use thereof *US6838443 (2005)*.
4. Cook, P.D., Manoharan, M., Guinosso, C.J. Amine-derivatized nucleosides and oligonucleosides *US6900297 (2005)*.
5. Jakobsen, M.H., Boas, U., Stenbaek, J.E.I., Heegaard, P.M.H. Method for introduction of reporter groups into bacterial lipopolysaccharide-derived carbohydrates and the subsequent coupling of such derivatives onto solid surfaces *US6881549 (2005)*.

ANTIMALARIAL ACTIVITY

1. Meunier, B., Robert, A., Dechy-Cabaret, O., Benoit-Vical, F. Dual molecules containing a peroxide derivative, synthesis and therapeutic applications thereof *US6949569 (2005)*.
2. Takeuchi, T., Wataya, Y., Inuma, M., Kim, H.-S., Watabe, H., Naganawa, H., Takahashi, Y. Compositions for treating or preventing malaria and method of treating malaria *US6939892 (2005)*.
3. Ishihara, Y., Suzuki, N., Takekawa, S. Melanin-concentrating hormone antagonist *US6930185 (2005)*.
4. Vial, H., Calas, M., Escale, R., Vidal, V., Bressolle, F., Ancelin, M.-L. Compounds with antiparasitic activity and medicines containing same *US20050176819A1 (2005)*.
5. Van, D. K. Method for potentiating primary drugs in treating multidrug resistant disease *US6911454 (2005)*.
6. Wataya, Y., Kim, H.-S., Nojima, M. Novel compounds and antimalarials *US20050131058A1 (2005)*.
7. Vennerstrom, J.L., Dong, Y., Chollet, J., Matile, H., Padmanilayam, M., Tang, Y., Charman, W.N. Spiro and dispiro 1, 2, 4-trioxolane antimalarials *US6906205 (2005)*.
8. Bowen, J.P., Robinson, T.P., Ehlers, T., Goldsmith, D., Arbiser, J. Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states *US6906105 (2005)*.
9. Bukrinsky, M., Cerami, A., Ulrich, P., Berger, B. Compounds and methods of use to treat infectious diseases *US6906076 (2005)*.
10. Kobayashi, S., Wataya, Y., Kim, H.S. Febrifugine, isofebrifugine and method for producing the same *US6844350 (2005)*.
11. Wataya, Y., Kim, H.S., Nojima, M. Novel compounds and antimalarials *EPI496056A1 (2005)*.
12. Sparatore, A., Taramelli, D., Basilico, N., Parapini, S., Sparatore, F., Boido, V., Canu Boido, C. 4-aminoquinoline quinolizidinyl- and quinolizidinylalkyl-derivatives with antimalarial activity. *WO05037833A1 (2005)*.

13. Solaja, B., Opsenica, D.M., Pocsfalvi, G., Milhous, W.K., Kyle, D.E Mixed steroidal 1, 2, 4, 5-tetraoxane compounds and methods of making and using thereof *US6906098 (2005)*.

ANTIVIRAL ACTIVITY

1. Rahal, J.J. Methods of treating West Nile virus infection *US6946125 (2005)*.
2. Janssens, F.E., Meersman, K.P.M.-J., Sommen, F.M., Guillemont, J.E.G., Lacrampe, J.F.A., Andries, K.J. L.M. Respiratory syncytial virus replication inhibitors *US6924287 (2005)*.
3. Ueda, Y., Connolly, T. P., Kadow, J.F., Meanwell, N.A., Wang, T., Chen, C.-P.H., Yeung, K.-S., Zhang, Z., Leahy, D.K., Pack, S.K, Soundararajan, N., Sirard, P., Levesque, K., Thoraval, D. Prodrugs of piperazine and substituted piperidine antiviral agents *US20050209246A1 (2005)*.
4. Bender, J.A., Yang, Z., Kadow, J.F., Meanwell, N.A. Diazaindole-dicarbonyl-piperazinyl antiviral agents *US20050124623A1 (2005)*.
5. Friedland, B., Hirschman, S.Z., Taraporewala, I.B. Preparation of a therapeutic composition *US6921542 (2005)*.
6. Kadow, J.F., Regueiro-Ren, A., Xue, Q.M. Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives *US6900206 (2005)*.
7. Yeung, K.-S., Farkas, M., Kadow, J.F., Meanwell, N.A., Taylor, M., Johnston, D., Coulter, T.S., Wright, J.J.K. Indole, azaindole and related heterocyclic N-substituted piperazine derivatives *US20050075364A1 (2005)*.
8. Chiacchio, U., Corsaro, A., Iannazzo, D., Macchi, B., Mastino, A., Piperno, A., Rescifina, A. Nucleoside analogues with antiviral activity *WO05082896A1 (2005)*.
9. Otto, M.J., Shi, J., Chu, C.K., Schinazi, R.F., Gumina, G., Chong, Y., Choi, Y. -2'- or 3'-halonucleosides *US6949522 (2005)*.
10. Kim, Y.-W., Kim, Y.-J., Choi, Y.-H., Ahn, J.-Y., Woo, S.-D., Sin, S.-W., Cho, M.-K., Byun, Y.H., Kang, J.-Y. Novel anti-viral vsf protein and hybridoma producing the same *US20050080236A1 (2005)*.
1. Averett, D.R., Webber, S.E., Lennox, J.R., Rueden, E.J. 3-*D*-Ribofuranosylthiazolo[4-5-*d*]pyridimine nucleosides and uses thereof *US6924271 (2005)*.
12. Ts'o Paul, O.P., Duff, R., Deamond, S. Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and method of use *US6906182 (2005)*.
13. Moorman, A.E., Becker, D.P., Flynn, D.L. Method of using (H⁺/K⁺) ATPase inhibitors as antiviral agents *US6906078 (2005)*.
14. Brothers, M.A., Duggal, R., Herlihy, K.J., Patick, A.K., Zhao, W. Dual reporter/dye reduction methodology for evaluating antiviral activity and cytotoxicity of hepatitis C virus inhibitors *WO04092402A1 (2005)*.
15. Zhong, S., Yu, H., Miller, R. Extracts of scutellaria for the treatment of SARS *WO05082388A1 (2005)*.
16. Taishi, T., Tada, Y. Naphthylidene derivative having hiv integrase inhibitory activity *WO05075475A1 (2005)*.
17. Bombardelli, E., Fontana, G. N-Deacetylthiocolchicine derivatives, their use and pharmaceutical formulations containing them *WO05075418A2 (2005)*.
18. Thurkauf, A., Chen, D., Phadke, A., Li, S., Deshpande, M. Azabenzofuran substituted thioureas as inhibitors of viral replication *WO05067900A3* and *WO05067900A2 (2005)*.
19. Mikamiyama, H., Iwata, M., Taoda, Y. Hydroxypyrimidinone derivative having HIV integrase inhibitory activity *WO05061490A1 (2005)*.
20. Fardis, M., Kim, C.U. 4'-substituted carbocir-and abacavir-derivatives as well as related compounds with HIV and HCV antiviral activity *WO05063751A1 (2005)*.
21. Ovidia, M. Antiviral preparations obtained from a natural cinnamon extract *WO05060352A2 (2005)*.
22. Thurkauf, A., Chen, D., Phadke, A., Li, S., Deshpande, M. Azabenzofuran substituted thioureas; inhibitors of viral replication *US20050228013A1 (2005)*.
23. Lee, B.-S., Shin, S.-H., Park, J.-S. Process for preparing 9-[4-acetoxy-3-(acetoxymethyl)but-1-yl]-2-aminopurine *US20050222413A1 (2005)*.
24. Liotta, D.C., Schinazi, R.F., Choi, W.B. Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1, 3-oxathiolane *US20050215527A1 (2005)*.
25. Boojamra, C.G., Cannizzaro, C., Chen, J.M., Chen, X., Cho, A., Chong, L.S., Fardis, M., Jin, H., Hirschmann, R.F., Huang, A.X., Kim, C.U., Kirschberg, T., Lee, C.P., Lee, W.A., MacKman, R.L., Markevitch, D.Y., Oare, D.A., Prasad, V.K., Pyun, H.J., Ray, A.S., Sherlock, R., Swaminathan, S., Watkins, W.J., Zhang, J.R. Antiviral phosphonate analogs *US20050215513A1 (2005)*.
26. Yuen, K.Y., Chen, F., Chan, K.H., Kao, Y.T., Guan, Y., Poon, L.L.M., Peiris, J. Baicalin, and its derivatives as a treatment for SARS coronavirus infection or other related infections *US20050215494A1 (2005)*.
27. Hershline, R. Antiviral composition *US20050209189A1 (2005)*.
28. Verbiscar, A.J. Formulations useful for the treatment of varicella zoster virus infections and methods for the use thereof *US20050203187A1 (2005)*.
29. Vaillant, A., Juteau, J.-M. Antiviral oligonucleotides targeting viral families *US20050196382A1 (2005)*.
30. Vaillant, A., Juteau, J.-M. Antiviral oligonucleotides *US20050176661A1 (2005)*.
31. Seth, P.P., Jefferson, E.A., Griffey, R.H., Swayze, E.E. Benzimidazoles and analogs thereof as antivirals *US20050165007A1 (2005)*.

32. Canan Koch, S.S., Alexander, T.N., Barvian, M., Bolton, G., Boyer, F.E., Jr., Burke, B.J., Holler, T., Jewell, T.M., Josyula, V.P., Kucera, D.J., Linton, M.A., Machak, J.J., Mitchell, L.J. Jr., Murphy, S.T. Reich, S.H., Skalitzky, D.J., Tatlock, J.H., Varney, M.D., Virgil, S.C., Webber, S.E., Worland, S.T., Melnick, M. HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis *US6953858 (2005)*.
 33. Faull, A., Barker, A.J., Kettle, J.G. Monocyte chemo-attractant protein-1 inhibitor compounds *US6953809 (2005)*.
 34. Tanaka, H., Hibino, K., Hijikata, Y. Composition having physiological activity and production method thereof *US6953580 (2005)*.
 35. Vaillant, A., Juteau, J.-M. Antiviral oligonucleotides targeting viral families *US20050153912A1 (2005)*.
 36. Swayze, E.E., Seth, P.P., Griffey, R.H., Jefferson, E.A. Benzimidazoles and analogs thereof as antivirals *US20050124638A1 (2005)*.
 37. Jones, D.S. Multivalent platform molecules comprising high molecular weight polyethylene oxide *US6951939 (2005)*.
 38. Harriman, G.C.B., Carson, K.G., Flynn, D.L., Solomon, M.E., Song, Y., Trivedi, B.K., Roth, B.D., Kolz, C.N., Pham, L., Sun, K.-I. Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefore *US6951848 (2005)*.
 39. Alton, N.K., Peters, M.A., Stabinsky, Y., Snitman, D.L. Manufacture and expression of large structural genes *US6936695 (2005)*.
 40. Boyer, F.E. Jr., Domagala, J.M., Ellsworth, E.L., Gajda, C.A., Lunney, E. A., Pavlovsky, A., Josyula, V. P. V. N. HIV protease inhibitors *US6927217 (2005)*.
 41. Vazquez, M.L., Mueller, R.A., Talley, J.J., Getman, D. P., DeCrescenzo, G.A., Freskos, J.N., Bertenshaw, D. E., Heintz, R.M. - and -amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors *US6924286 (2005)*.
 42. Bookser, B.C., Dang, Q.R.K. Phenyl phosphonate fructose-1, 6-bisphosphatase inhibitors *US6919322 (2005)*.
 43. Green, H., Compton, B., Corey, G., Djian, P. Conjugates of agents and transglutaminase substrate linking molecules *US6919076 (2005)*.
 44. McLaughlin, L.W., Fraley, A.W., Chen, D.L., Lan, T. Selective anti-viral nucleoside chain terminators *US6914052 (2005)*.
 45. Faull, A.W., Kettle, J. Anti-inflammatory indole derivatives *US6911465 (2005)*.
 46. Schinazi, R.F., Liotta, D.C., Chu, C.K., McAtee, J.J., Shi, J., Choi, Y., Lee, K., Hong, J.H. 2'-fluoro-nucleosides *US6911424 (2005)*.
 47. Yu, K.-L., Civiello, R.L., Krystal, M.R., Kadow, K.F., Meanwell, N.A. Substituted benzimidazole antiviral agents *US6908936 (2005)*.
 48. Watanabe, K.A., Shi, J., Otto, M.J. N⁴-acylcytosine-1, 3-dioxolane nucleosides for treatment of viral infections *US6908924 (2005)*.
 49. Cook, P.D., Sanghvi, Y.S., Vasseur, J.J., Debart, F. Backbone modified oligonucleotide analogues *US6900301 (2005)*.
 50. Slade, H.B. Method for the treatment of dermal lesions caused by envenomation *US6894060 (2005)*.
 51. Lee, F.Y., L, F.C., Yang, C.A., Yong, M.W., Wu, X.A., Ye, W.Q., Hua, X.X. 9H-imidazo[1, 2-a]purin-9-one compounds. *US6887997 (2005)*.
 52. Shouming, Z., Hongwen, Y., Robert, M. Use of Scutellaria for the treatment of viral infections *GB2411354A1 (2005)*.
 53. Murai, H., Endo, T., Kurose, N., Taishi, T., Yoshida, H. Heterocyclic compound having HIV integrase inhibitory activity *EP1541558A4 (2005)*.
 54. Uckun, F.M., Rajamohan, F. Pokeweed antiviral protein polypeptides with antiviral activity *EP1567640A2 (2005)*.
 55. Wang, T., Zhang, Z., Meanwell, N. A., Kadow, J.F., Yin, Z., Xue, Q.M., Regueiro-Ren, A., Matiskella, J.D., Ueda, Y. Composition and antiviral activity of substituted azaindoxoaacetic piperazine derivatives *EP1549313A1 (2005)*.
 56. Murai, H., Endo, T., Kurose, N., Taishi, T., Yoshida, H. Heterocyclic compound having HIV integrase inhibitory activity *EP1541558A1 (2005)*.
 57. Wallace, O.B., Wang, T., Yeung, K.-S., Pearce, B.C., Meanwell, N.A., Qiu, Z., Fang, H., Xue, Q.M., Yin, Z. Composition and antiviral activity of substituted indoleoxoaacetic piperazine derivatives *EP1299382B1 (2005)*.
 58. Ubasawa, M., Sekiya, K., Takashima, H., Ueda, N., Yuasa, S., Kamiya, N. Phosphonate Nucleotide Compounds *CA2195262C (2005)*.
- ANTI - INFECTIVE AND ANTI - BACTERIAL AGENTS**
1. Ma, Z., Nemoto, P., Zhang, S., Yong, H., Or, Y.S. Anti-infective agents useful against multidrug-resistant strains of bacteria *US6946446 (2005)*.
 2. Asahina, Y., Takei, M. 7-(4-Substituted 3- cyclopropyl-aminomethyl-1- pyrrolidinyl) quinolonecarboxylic acid derivative *WO05026147A1 (2005)*.
 3. El-Ahmad, Y., Leconte, J.-P., Malpart, J., Mignani, S., Mutti, S., Tabart, M. Novel process for preparing 3-fluoroquinolones *US20050182259A1 (2005)*.
 4. Porter, J.R., Head, J.C., Warrelow, G.J., Archibald, S.C. -alanine derivatives *US6953798 (2005)*.
 5. Sunagawa, M., Sasaki, A. Novel carbapenem compounds *US20050020566A1 (2005)*.

6. Davies, D.T., Markwell, R.E., Pearson, N.D., Takle, A.K. Quinoline derivatives as antibacterials **US6911442 (2005)**.
7. Takemura, M., Takahashi, H., Kawakami, K., Itoh, M., Suzuki, T., Ohtani, T., Sekiguchi, M., Miyauchi, R., Hayakawa, I. Quinolonecarboxylic acid derivative. **US6900225 (2005)**.
8. Surivet, J.-P., Zumbunn, C., Hubschwerlen, C., Perez Frutos H. Novel compounds with antibacterial act **EP1551829A2 (2005)**.
9. Botyanszki, J., Shi, D.-F., Roberts, C.D. Gezginci, M.H., Valdez, S.C., Sattarzadeh, S. Novel aromatic compounds possessing antifungal or antibacterial activity. **EP1556035A2 (2005)**.
10. Davies, D.T., Elder, J.S., Forrest, A.K., Jarvest, R.L., Pearson, N.D., Sheppard, R.J. Aminocyclohexene quinolines and their azaisosteric analogues with antibacterial activity **EP1539133A1 (2005)**.
11. Yu, J., Lee, J., Kwon, M., Pae, A.N., Koh, H.Y. Heterodimeric conjugates of neomycin-oxazolidinone, their preparation and their use **US20050222055A1 (2005)**.
12. Turos, E. N-thiolated beta-lactams: novel antibacterial agents for methicillin-resistant *Staphylococcus aureus* **US6946458 (2005)**.
13. Chen, Q.-Q., Griffin, J.H., Jenkins, T.E., Judice, J.K., Linsell, M.S., Leadbetter, M.R., Mu, Y.Q. Novel antibacterial agents **US20050171010A1 (2005)**.
14. Agarwal, S.K., Guha, M.K., Pandey, S.S., Samuel, M. M. Novel antibacterial agents **EP1578734A1 (2005)**.
15. Wright, G.E., Xu, W.-C., Brown, N.C. Purine and isosteric antibacterial compounds **US6926763 (2005)**.
16. Gazit, E., Cherny, I. Novel antibacterial agents and methods of identifying and utilizing same **WO05031362A2** and **WO05031362A3 (2005)**.
17. Agarwal, S.K., Guea, M.K. Pandey, S.S., Samuel, M. M. Novel antibacterial agents **US20050070526A1 (2005)**.
18. Wolfe, S., Shustov, G. Oxazinones and methods for their use and synthesis **US6861416 (2005)**.
19. Chen, Y., Tan, X.X. Oligodeoxynucleotide intervention for prevention and treatment of sepsis **US20050020526A1 (2005)**.
- Reddy, T.J., Zhang, M.-Q. Compounds and methods for the treatment or prevention of i flavivirus /i infections **EP1569929A1 (2005)**.
5. Rosenquist, Å., Thorstensson, F., Johansson, P.-O., Kvarnström, I., Ayesa, S., Classon, B., Rakos, L., Samuelsson, B. HCV NS-3 Serine protease inhibitors **WO05073216A3 (2005)**.
6. Gourdin, G.T., Richheimer, S.L., Bailey, D.T., Nichols, R.L., Freeberg, D.R., Tempesta, M.S., Daugherty, J.F. Compositions enriched in phenolic compounds and methods for producing the same **WO05072762A1 (2005)**.
7. Stapleton, J.T., Xiang, J., Klinzman, D., McLinden, J.H. GB virus C (hepatitis G virus) for the treatment of HIV **US20050118181A1 (2005)**.
8. Keicher, J.D., Roberts, C.D., Dyatkina, N.B. Nucleoside compounds for treating viral infections **WO05042556A1 (2005)**.
9. Chan C.K.L., Pereira, O.Z., Nguyen-Ba, N., Reddy, T.J., Das, S.K., Siddiqui, M.A. Compounds and methods for the treatment or prevention of flavivirus infections **US6936629 (2005)**.
10. Lemon, S.M., Yi, M. Replication competent hepatitis C virus and methods of use **US6921634 (2005)**.
11. Chan, C.K.L., Bedard, J., Das, S.K., Nguyen B.N., Pereira, O.Z., Shuttleworth, S.J. Compounds and methods for the treatment or prevention of flavivirus infections **US6887877 (2005)**.
12. Borchardt, A.J., Goble, M.P. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same **US6878727 (2005)**.
13. Garry, R.F., Dash, S., Coy, D.H., Mckeating, J.A. Flavivirid fusion inhibitors **EP1558276A2 (2005)**.
14. Sommadossi, J.-P., La Colla, P., Storer, R., Gosselin, G. Modified 2' and 3' -nucleoside prodrugs for treating flaviridae infections **EP1523489A2 (2005)**.
15. Weiner, D.B., Yang, J.-S. Compositions and methods of using capsid protein from flaviviruses and pestiviruses **EP1322338A4 (2005)**.
16. Arroyo, J., Miller, C., Catalan, J.A., Monath, T.P. West Nile virus vaccine **US20050053624A1 (2005)**.
17. Khromykh, A.A., Hall, R. West Nile virus vaccine **WO05042014A1 (2005)**.

FLAVIVIRUSES

1. Weiner, D.B., Yang, J.-S., Muthumani, K. Compositions and methods of using capsid protein from Flaviviruses and Pestiviruses **US20050226849A1 (2005)**.
2. Monath, T.P., Guirakhoo, F., Arroyo, J., Pugachev, K. Flavivirus vaccine **WO05082020A2 (2005)**.
3. Apt, D., Punnonen, J., Brinkman, A.M. Novel flavivirus antigens **EP1572941A2 (2005)**.
4. Chan, C.L., Das, S.K., Nguyen-Ba, N., Halab, L., Hamelin, B., Pereira, O.Z., Poisson, C., Proulx, M.,
18. Storer, R., Gosselin, G., Dukhan, D., Leroy, F. Purine nucleoside analogues for treating Flaviviridae including hepatitis C **US20050075309A1 (2005)**.
19. Chan C.K.L., Das, S.K., Nguyen-Ba, N., Halab, L., Hamelin, B., Pereira, O.Z., Poisson, C., Proulx, M., Reddy, T.J., Ming-Qiang, Z. Compounds and methods for the treatment or prevention of Flavivirus infections **US20050009804A1 (2005)**.

ANTIOXIDANTS

1. Demopolos, H.B., Seligman, M.L. Pharmaceutical preparations of glutathione and methods of administration thereof *US6896899 (2005)*.
2. Wittig, B., Fuertes-López, L., Timón-Jiménez, M. Agent for treating leishmania infections *WO05039633A1 (2005)*.
3. Zabrecky, G. Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis *US20050123628A1 (2005)*.
4. Maes, L.J.R.M., Germonprez, N.A.G., Van Puyvelde, L.E.M., De Kimpe, N.G.M., Ngoc N.T. Antiprotozoal saponins *US6872713 (2005)*.
5. Dixit, D., Pushpangadan, P., Kochhar, V.K., Kochhar, S., Rao, C.V. Novel and stable enzymatic antioxidant defense system in *Curcuma longa* l *WO05017134A2 (2005)*.
6. Fergusson, A., Davidson, J.C. Composition for the regulation of the human immune system and the prevention and treatment of diseases thereof *US20050182037A1 (2005)*.
7. Smith, J.B. Anti-viral compositions and methods of making and using the anti-viral compositions *US6855341 (2005)*.
8. Smith, J.B. Anti-viral compositions and methods of making and using the anti-viral compositions *US20050003020A1 (2005)*.
9. Liu, S. N-substituted 3-hydroxy-4-pyridinones and pharmaceuticals containing thereof *US6932960 (2005)*.
10. Montagnier, L. Combined treatments and methods for treatment of mycoplasma and mycoplasma-like organism infections *US20050164173A1 (2005)*.
11. Smith, H.J. Method of treating viral infections *WO05016370A1 (2005)*.
12. Brass, C.A., Glue, P.W., Piken, E. HCV combination therapy *US6849254 (2005)*.
13. Romanczyk, L.J. Jr., Kozikowski, A.P., Tueckmantel, W., Lippman, M.E. Synthetic methods for polyphenols *US6849746 (2005)*.
14. Fogelman, A.M., Anantharamaiah, G.M., Navab, M. Orally administered peptides to ameliorate atherosclerosis *US6933279 (2005)*.
15. Chen, I.-J. KMST isoeugenol derivatives and pharmaceutical activity *US6887878 (2005)*.
16. Bailey, S., Gautier, E.C.L., Henderson, A.J., Magee, T.V., Marfat, A., Mathias, J.P., McLeod, D.G., Monaghan, S.M., Stammen, B.L.C. Nicotinamide derivatives useful as PDE4 inhibitors *US6949573 (2005)*.
17. Castelhana, A., McKibben, B., Witter, D.J. Compounds specific to adenosine A1 receptor and uses thereof *US6878716 (2005)*.
18. Winchell, H.S. Neuroprotection and cardioprotection afforded by chelators with high affinity and specificity for cations of first transition series elements *US6881732 (2005)*.
19. Ajami, A.M., Sims, C.A., Fink, M.P. Pyruvate ester composition and method of use for resuscitation after events of ischemia and reperfusion *US6846842 (2005)*.
20. Pfeleiderer, W., Schmidt, H., Henning, R. Use of tetrahydropteridine derivatives as no synthase inhibitors *US6858612 (2005)*.
21. Stanton, G.J., Hughes, T.K., Jr., Boldogh, I. Use of colostrinin, constituent peptides thereof, and analogs thereof, as oxidative stress regulators *US6939847 (2005)*.
22. Stamler, J.S., Chen, Z., Munzel, T. Reversing, postponing or preventing the occurrence of GTN tolerance and/or generation of reactive oxygen species from mitochondria *WO05051369C1 (2005)*.
23. Sheu, S.-S., Anders, M.W., Xu, L. Sharma, V.K. Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof *WO05051978A2 (2005)*.
24. Harnett, J., Auguet, M. New heterocyclic or benzenic derivatives of lipoic acid, their preparation and their use as medicaments *US20050227991A1 (2005)*.
25. Jia, Q., Farrow, T.M. 7-Hydroxy chromones as potent antioxidants *US20050164957A1 (2005)*.
26. Lockwood, S.F., O'Malley, S., Watumull, D.G., Hix, L.M., Jackson, H., Nadolski, G., Carotenoid analogs or derivatives for the inhibition and amelioration of disease *US20050113372A1 (2005)*.
27. Gonzalez-Cadavid, N.F., Rajfer, J. Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases *US20050085486A1 (2005)*.
28. Lockwood, S.F., O'Malley, S., Watumull, D.G., Hix, L.M., Jackson, H., Nadolski, G. Pharmaceutical compositions including carotenoid analogs or derivatives for the inhibition and amelioration of disease *US20050075337A1 (2005)*.
29. Baker, J.R., Cooper, G.J.S. Fructosamine oxidase: antagonists and inhibitors *US6897243 (2005)*.
30. Rotta, A.T., Fuhrman, B.P., Gunnarsson, B., Steinhorn, D.M., Hernan, L.J. Method for reducing free-radical induced injury *US6894079 (2005)*.
31. Shashoua, V.E. Compositions and methods for counteracting effects of reactive oxygen species and free radicals *US6890896 (2005)*.
32. Jia, Q., Farrow, T.M. 7-Hydroxy chromones as potent antioxidants *US6884783 (2005)*.
33. Fotinos, S., Panaitescu, L., Skaltsounis, A.-L., Mitakou, S., Magiatis, P., Aligiannis, N., Galaris, D. Compounds and compositions derived from olives and methods of the use thereof *US6906100 (2005)*.

34. Stanton, G.J., Hughes, T.K. Jr., Boldogh, I. Georgiades, J.A. Use of colostrinin, constituent peptides thereof, and analogs thereof for inducing cytokines *US6903068 (2005)*.
 35. Henderson, T.R., Corson, B.E. L-Ergothioneine, milk thistle, and S-adenosylmethionine for the prevention, treatment and repair of liver damage *US6863906 (2005)*.
 36. Romanczyk, L.J.Jr., Schmitz, H.H. Compositions for, and methods of, treating atherosclerosis *US6900241 (2005)*.
 37. Kim, Darrick S.H.L. Pharmaceutical compositions useful in prevention and treatment of beta-Amyloid protein-induced disease *US6887898 (2005)*.
 38. Broughton, S.J., Gharu, R.K., Leow, M.Y.T., Neale, P.J. (2S)-2-Amino-a-[[2- (ethanimidoylamino) ethyl]thio] butanoic acid, a nitric oxide synthase inhibitor, in stabilized pharmaceutical dosage forms *US2005022260A1 (2005)*.
 39. Song, J. Method and material for free radical scavenging in human tissue *US2005017680A1 (2005)*.
 40. Cooper, G.J.S., Baker, J.R. Preventing and/or treating cardiovascular disease and/or associated heart failure *US6951890 (2005)*.
 41. Chen, W.-J. Prevention of atherosclerosis and restenosis *US6939863 (2005)*.
 42. Simon, J.E., Wang, M., Gbewonyo, K., Rafi, M.M., Acquaye, D.F., Asianowa, Y. Antioxidant and anti-inflammatory activity of compounds and preparations from African nutmeg seeds *US20050003030A1 (2005)*.
 43. Meng, C.Q., Hoong, L.K., Somers, P.K. Thioketals and thioethers for inhibiting the expression of VCAM-1 *US6852878 (2005)*.
- ANTI-TUBERCULOSIS DRUG**
1. Arora, S.K., Patil, V.J., Nair, P.S., Dixit, P.P., Ajay, S., Sinha, R.K. Novel antimycobacterial compounds *US20050192275A1 (2005)*.
 2. Sapte, V.R. Oral cyclodextrin complexes of anti-tuberculosis drug *WO05074937A1 (2005)*.
 3. Sapte, V.R. Enhancing the efficacy of tubercular drugs *US20050171116A1 (2005)*.
 4. Sen, H., Jayanthi, S., Sinha, R., Sharma, R., Muttill, P. Microsphere of two anti-tubercular drugs and a biodegradable polymer administered by inhalation alone or combined with oral route, and process thereof *WO05039529A1 (2005)*.
 5. Sen, H., Jayanthi, S., Sinha, R., Sharma, R., Muttill, P. Inhalable biodegradable microparticles for target-specific drug delivery in tuberculosis and a process thereof *US20050084455A1 (2005)*.
- ANTIMYCOBACTERIAL ACTIVITY**
1. Thomas, R.C., Poel, T.-J., Barbachyn, M.R., Gordeev, M.F., Luehr, G.W., Renslo, A., Singh, U. N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives *US6919329 (2005)*.
 2. Bowen, J.P., Robinson, T.P., Ehlers, T., Goldsmith, D., Arbiser, J. Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states *US6906105 (2005)*.
 3. Arora, S.K., Sinha, N., Jain, S., Upadhayaya, R.S., Jana, G., Ajay, S., Sinha, R. Pyrrole derivatives as antimycobacterial compounds *US20050107370A1 (2005)*.
 4. Reed, S.G., Skeiky, Y.A.W., Dillon, D.C., Campos-Neto, A., Houghton, R., Vedvick, T.S., Twardzik, D.R., Lodes, M.J., Hendrickson, R.C. Compounds and methods for diagnosis of tuberculosis *US6949246 (2005)*.
 5. Barletta, R.G., Barletta-Chacon, O. D-alanine racemase mutants of mycobacteria and uses therefore *US6929799 (2005)*.
 6. Tsubouchi, H., Sasaki, H., Itotani, M., Haraguchi, Y., Miyamura, S., Matsumoto, M., Hashizume, H., Tomishige, T., Kawasaki, M., Ohguro, K., Sumida, T., Hasegawa, T., Tanaka, K., Takemura, I. 2, 3-Hydro-6-nitroimidazo (2, 1-b) oxazole compounds for the treatment of tuberculosis *WO05042542A1 (2005)*.
 7. Lund, O., Lundegaard, C., Nielsen, M., Worning, P., Deans, R.J., Buus, S., Brunak, S. T cell epitopes useful in *Mycobacterium tuberculosis* vaccine and as diagnostic tools and methods for identifying same *WO05038000A2 (2005)*.
 8. Heifets, L., Sanchez, T. Method for testing drug susceptibility of *Mycobacterium tuberculosis* *US6951733 (2005)*.
 9. Singh, M., Colnaghi, M.I., Colombo, M.P., Balsari, A. Vector comprising *Mycobacterium tuberculosis* 38 kDa antigen for neoplasm treatment *EP0926156B1 (2005)*.
 10. Mizzen, L.A., Siegel, M., Liu, H. Hepatitis B virus treatment *US6921534 (2005)*.
 11. Concepcion, G.P., Ireland, C.M., Mangalindan, G.C., Davis, R.A., Tasdemir, D., Boho, Z.P., Rodriguez, N.O., Antemano, D.R., De Guzman, D.D., Samson, S.C., Harper, M.K. Cyclic hexapeptides, process and use thereof *WO05085277A1 (2005)*.
 12. Salman, M., Biswajit, D., Rudra, S., Yadav, A.S., Rattan, A. Oxazolidinone derivatives as antimicrobials *WO05082899A1 (2005)*.
 13. Bercovier, H., Barenholz, A., Gershoni, J. Peptide mimotopes of mycobacterial mannosylated lipoglycans and uses thereof *WO05080414A1 (2005)*.
 14. Rhee, J.K., Im, W.B., Cho, C.H., Choi, S.H., Lee, T.H. Novel oxazolidinone derivatives *WO05058886A1 (2005)*.
 15. Cardona iglesias, P.J., Mata R.I. Immunotherapeutic agent which is used for the combined treatment of tuberculosis together with other pharmaceuticals *WO05042013A1 (2005)*.
 16. Hamblin, P.A., Rocha Del Cura, M. de los A. Vaccines *WO05025612A1 (2005)*.

17. Cappelli, G., Mariani, F., Colizzi, V. Use of gene sequences specific for *Mycobacterium tuberculosis* and their related proteins for diagnosis and prevention of tubercular infection **WO05021790A3 (2005)**.
 18. Lee, R.E., Tangallapally, R.P., McNeil, M.R., Lenaerts, A. Heterocyclic amides with anti-tuberculosis activity **WO05007625A2 (2005)**.
 19. Gicquel, B., Portnoi, D., Lim, E.-M., Pelicic, V., Guigueno, A., Goguet De La S.Y. Polypeptide nucleic sequences exported from mycobacteria, vectors comprising same and uses for diagnosing and preventing tuberculosis **US20050158714A9 (2005)**.
 20. Hearn, M.J. Antimycobacterial compounds and method for making the same **US6846933 (2005)**.
 21. Hanumanthappa, K.P., Prabhakar, S., Mishra, A., Sivaswami, T.J. The characterization of hupB gene encoding histone like protein of *Mycobacterium tuberculosis* **EP1581659A1 (2005)**.
 22. Tsubouchi, H., Sasaki, H., Kuroda, Hideaki; Itotani, M., Hasegawa, T., Haraguchi, Y., Kuroda, T., Matsuzaki, T., Tai, K., Komatsu, M., Matsumoto, M., Hashizume, H., Tomishige, T., Seike, Y., Kawasaki, M., Sumida, T., Miyamura, S. 2, 3-Dihydro-6-nitroimidazo [2, 1-b] oxazoles **EP1555267A1 (2005)**.
 23. Kabbash, C., Shuman, H.A., Silverstein, S.C., Della-Latta, P. Novel antimicrobial activity of gemfibrozil **EP0888049A4 (2005)**.
 24. Liu, M.A., Montgomery, D., Ulmer, J., Content, J., Huygen, K. A polynucleotide tuberculosis vaccine **EP0792358B1 (2005)**.
 25. Lee, R.E., Tangallapally, R.P., Yendapally, R., McNeil, M., Lenaerts, A. Heterocyclic amides with anti-tuberculosis activity **US20050222408A1 (2005)**.
 26. Fukuda, Y., Hammond, M.L. Bicyclo[3.1.0]hexane containing oxazolidinone antibiotics and derivatives thereof **US20050203144A1 (2005)**.
 27. Tidwell, R.R., Werbovetz, K., Franzblau, S.G., Bakunova, S., Bakunov, S. Cationic substituted benzofurans as antimicrobial agents **US20050197378A1 (2005)**.
 28. Van Gestel, J.F.E., Guillemont, J.E.G., Venet, M.G., Poinet, H.J.J., Decrane, L.F.B., Vernier, D.F.J., Odds, F.C. Novel mycobacterial inhibitors **US20050148581A1 (2005)**.
 29. Montaines, C.M., Gicquel, B., Perez H.E. Reduction in the virulence of *Mycobacterium tuberculosis* and protection against tuberculosis by means of phoP gene inactivation **US20050106175A1 (2005)**.
 30. Fukuda, Y. Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof **US20050038092A1 (2005)**.
 31. Gopalan, V., Jovanovic, M., Eder, P.S., Giordano, T., Powers, G.D., Xavier, K.A. Bacterial RNase P proteins and their use in identifying antibacterial compounds **US6936432 (2005)**.
 32. Schroder, U., Svenson, S. Vaccine composition **US6936260 (2005)**.
 33. Fukuda, Y., Hammond, M.L. Bicyclo[3/1/0] hexane containing oxazolidinone antibiotics and derivatives thereof **US6897230 (2005)**.
 34. Schroder, U., Svenson, S. Vaccine formulation **US6890540 (2005)**.
 35. Simard, J.J.L., Diamond, D. Method of epitope discovery **US6861234 (2005)**.
- SIGMA FACTOR**
1. Bassler, B.L., Surette, M.G. Compositions and methods for regulating bacterial pathogenesis **US6942986 (2005)**.
 2. Bassler, B.L., Surette, M.G. Compositions and methods for regulating bacterial pathogenesis **US6936435 (2005)**.
 3. Pearson, J.P., Gray, K.M., Passador, L., Tucker, K.D., Eberhard, A., Iglewski, B.H., Greenberg, E.P. Autoinducer molecule **US6936447 (2005)**.
 4. Möckel, B., Hermann, T., Farwick, M., Binder, M., Pfefferle, W. Methods of making L-amino acids in coryneform using the sigE gene **US6913908 (2005)**.
 5. Bathe, B., Kreutzer, C., Martens, M., Farwick, M., Hermann, T., Pfefferle, W. Methods for producing amino acids in coryneform bacteria using an enhanced sigD gene **US6890744 (2005)**.
 6. White, A.P., Doran, J.L., Collinson, S.K., Kay, W.W. Bacterial fimbrial system for presentation of heterologous peptide sequences **US6864365 (2005)**.
 7. Whiteley, M., Lee, K.M., Greenberg, E.P., Muh, U. Quorum sensing signaling in bacteria **US6855513 (2005)**.
 8. Bathe, B., Hans, S., Kreutzer, C., Pfefferle, W. Alleles of the sigma gene from coryneform bacteria **US20050043526A1 (2005)**.
- ISOCITRATE LYASE**
1. Hanke, P.D., Li-D'Elia, L.-Y., Walsh, H.J., Crafton, C.M., Rayapati, P.J. Increased lysine production by gene amplification using coryneform bacteria **US6927046 (2005)**.
 2. Meyer, C. Method for identifying a compound for the treatment of microorganism infections by inhibiting energy storage and utilization in pathogens **US6852485 (2005)**.
- SERINE/THREONINE KINASES**
1. Pandol, S.J., Gukovskaya, A. Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof **US6953786 (2005)**.
 2. Liou, J.-R. Regulation of human serine / threonine kinase **US20050214768A1 (2005)**.
 3. Hemmings, B.A., Millward, T.A. Nuclear protein serine/threonine kinases **EP0793725B1 (2005)**.

4. Birault, V., Harrison, S.A. Imidazo '1, 2-A' pyrazine compounds which interact with protein kinases **WO05085252A1 (2005)**.
5. Agrez, M.V., Ahmed, N. Map kinase integrin-binding domain **US20050214755A1 (2005)**.
6. Nabel, G.J., Nabel, E.G., Boehm, M. hKIS compositions and methods of use **US20050203050A1 (2005)**.
7. Popoff, I.J., Van Arsdale, T.L. Antisense oligonucleotides and RNA-interfering molecules targeting PAK4 **US20050191672A1 (2005)**.
8. Lang, F., Waldegger, S. Cell volume-regulated human kinase h-sgk **US20050181402A1 (2005)**.
9. Pease, E.J., Williams, E.J., Bradbury, R.H., Pearson, S.E. 2, 4, DI (hetero-) arylamino (-oxy) -5-substituted pyrimidines as antineoplastic agents **US20050090515A1 (2005)**.

10. Bird, T.G.C. Benzoxazinone derivatives for use in the treatment of angiogenesis **US6951855 (2005)**.

RNA POLYMERASE AND TUBERCULOSIS

1. Lee, H., Park, Y.K., Bai, G.-H., Kim, S.-J., Cho, S.-N. Kim, Y., Park, H.J. rpoB Gene fragments and a method for the diagnosis and identification of *Mycobacterium tuberculosis* and non-tuberculosis Mycobacterial strains **US6951718 (2005)**.
2. Balganes, M., Sharma, U. DNA Molecules **US6921813 (2005)**.
3. Yang, M., Woo, H.S. Mutation detection on RNA polymerase beta subunit gene having rifampin resistance **US6902894 (2005)**.